Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

25.08.2023 - The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis ...

Related Keywords

Athens ,Attikír ,Greece ,Bristol Myers Squibb ,Narinder Bhalla ,Twitter ,Linkedin ,Exchange Commission ,Facebook ,Pfizer Alliance The ,Instagram ,Pfizer Inc ,Youtube ,Pfizer ,Clinformatics Data Mart ,Senior Vice President ,Worldwide Medical ,Established Brands ,Bristol Myers ,Hazard Ratio ,Confidence Interval ,Non Valvular Atrial Fibrillation ,Approved Indications ,Thrombotic Events ,Premature Discontinuation ,Epidural Anesthesia ,Heart Valves ,Hemodynamically Unstable Patients ,Require Thrombolysis ,Pulmonary Embolectomy ,Triple Positive Antiphospholipid Syndrome ,Antiplatelet Agents ,Bristol Myers Squibb Pfizer ,Bristol Myers Squibb Pfizer Alliance ,Myers Squibb ,Breakthroughs That Change Patient ,Pfizer News ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Looking Information ,Factors That May Affect Future Results ,Bristol Myers Squibb Aktie ,Fizer Aktie ,